An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Globally, colorectal cancer (CRC) continues to rank among the leading causes of cancer-related death. Systemic toxicity, multidrug resistance, and nonspecific targeting often pose challenges to conventional therapy for CRC. Because it is a complex disease with a complex genetic and environmental pathophysiology, advanced therapeutic strategies are needed. Nanotechnology presents a potential solution that may maximize therapeutic efficacy while minimizing negative effects by enabling personalized delivery of anticancer drugs. This review focuses on recent developments in colorectal drug delivery systems based on nanotechnology. Numerous nanomaterials, including liposomes, dendrimers, micelles, exosomes, and gold nanoparticles, are developed and used. Distinctive characteristics of mentioned nanocarriers are discussed along with strategies that can be employed for enhancing the delivery of drugs to colorectal cancer cells. The review also quotes the most relevant preclinical and clinical studies that show how these nanomaterials improve drug solubility, stability, and targeted delivery while overcoming the shortcomings of conventional therapies. Nanotechnology has made CRC treatment very efficient and advanced, which has opened up new possibilities for targeted drug delivery. Preclinical and clinical studies have also proved that the use of nano-formulations in colon-specific delivery systems have significant results, indicating potential for better patient outcomes. Future res…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, several nanocarriers have been created to specifically address MDR in CRC therapy by co-delivering chemotherapy drugs and ABC transporter inhibitors [109].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [109]
Citations
Cites
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
de Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30488-7 · Cited by 2,475
Global colorectal cancer burden in 2020 and projections to 2040
Xi, Y., & Xu, P. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101174 · Cited by 2,434
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Sawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920 · cited 1×
“1 (Hossain et al. 2022).”
Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
Smeu, A., Marcovici, I., Dehelean, C. A., Dumitrel, Ș.-I., Borza, C., & Lighezan, R. (2025) · Pharmaceuticals · doi:10.3390/ph18020231 · Cited by 29
Advances in nanotechnology for colorectal cancer: a smart targeting and theranostics approach
Sahoo, S. P., Samal, S., Sahu, R., & Acharya, B. (2025) · Medical Oncology · doi:10.1007/s12032-025-02910-2 · Cited by 15
Organic nanoplatforms for metallodrugs delivery: Current advances in colorectal cancer
Neto, Í., Rocha, J. P., Gaspar, M. M., & Reis, C. P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189547 · Cited by 7
Boufissiou, A., Abdalla, M., Kadi, I., Hachani, S., Eltayb, W. A., Awadalla, M., Algarni, A. S., Benarfa, A., Bouchareb, A., Benaceur, F., et al. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00543-z · Cited by 5
Ma, M., Yan, G., & Huang, G. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1784740 · Cited by 3
Dudhwala, Y. D., Shah, D. P., Haswani, N. G., Kapoor, D. U., Prajapati, B. G., Alsaidan, O. A., & Alzarea, S. I. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127098 · Cited by 3
Kundu, R. K., Kibria, H. B., Ahamed, M. F., & Chowdhury, M. E. H. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.110566 · Cited by 1
Yang, Z.-H., Huang, Q.-L., Luo, L., Wu, X.-X., Nie, S.-W., & Xu, M. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121133
Nazari, M., Khaleghi, S., Farjam, T. B., & Hajrasouliha, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-65782-0
Metadata
- Authors
- Shahzad, M., Hameed, H., Amjad, A., Khan, M. A., Qureshi, I. S., Hameed, A., Saeed, A., & Munir, R.
- Affiliations
- University of Central Punjab (PK)
- Lahore University of Biological and Applied Sciences (PK)
- Riphah International University (PK)
- Government College University, Faisalabad (PK)
- Corresponding author
- Hameed, Huma
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2024-10-03
- Volume
- 398
- Issue
- 3
- Pages
- 2107-2125
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W4403106438
- Cited by
- 7
- References
- 126
- Citations by year
- 2026: 4 · 2025: 3
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Naunyn-Schmiedeberg s Archives of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
- Keywords
- colorectal cancer, colon cancer, targeted drug delivery, nanocarriers, liposomes, dendrimers, micelles, exosomes, gold nanoparticles, multidrug resistance, colon-targeted drug delivery, drug solubility and stability, biocompatibility, nanomedicine regulation
- MeSH terms
- Nanoparticle Drug Delivery System, Animals, Antineoplastic Agents, Colonic Neoplasms, Drug Carriers, Humans, Drug Delivery Systems, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.